drugset / Trial / NCT03535935

Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease

NCT03535935 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

This add-on open-label randomised controlled pragmatic trial aims to: 1. evaluate the effect of add-on astragalus treatment on type 2 diabetic patients with stage 2 to 3 chronic kidney disease and macroalbuminuria. 2. estimate treatment effect, variance, recruitment rate, attrition rate and change in clinical manifestation including Chinese medicine syndrome for parameters optimisation and feasibility assessment for a subsequent phase III randomised controlled trial. 3. assess response predictors for efficacy and safety among type 2 diabetic patients with stage 2 to 3 chronic kidney disease and macroalbuminuria receiving add-on astragalus treatment

Timeline

Start
2018-07-01
Primary completion
2022-06-30
Completion
2022-12-31

Outcome

Mixed primary results

paper the estimated difference in the slope of eGFR decline was 4.6 ml/min/1.73m2 per year (95 %CI: 1.5 to 7.6, p = 0.003) slower with astragalus. PMID 38810556 ↗

paper For UACR, the estimated inter-group proportional difference in the slope of change was insignificant (1.14, 95 %CI: 0.85 to 1.52, p = 0.392). PMID 38810556 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Astragalus Powder Traditional medicine (herbal / TCM) 3 g Oral